Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer

Completed · Phase 2 · Has a placebo group

Conditions studied: Bone Loss, Prostate Cancer

In brief

The primary objective of this study is to determine whether zoledronic acid (Zometa) given once annually increases bone mineral density in men receiving hormone therapy for prostate cancer.

Key facts

Study ID

NCT00181584

Run by

Massachusetts General Hospital

People needed

60

Starts

2003-09-01

Last updated by the study team

2013-07-11

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Adenocarcinoma of the prostate
• Current androgen deprivation therapy with expected duration of treatment greater than or equal to 12 months
• Corrected serum calcium > 8.4mg/dl and < 10.6mg/dl
• Serum creatinine < 2.0mg/dl

You may not qualify if…

• History of bone metastases by bone scan
• Treatment with bisphosphonate within one year
• History of metabolic disease
• Chronic use of glucocorticoids, anticonvulsants, or suppressive doses of thyroxine within one year

Where it is running

• Massachusetts General Hospital — Boston, Massachusetts, United States
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.